⁍ France’s Ose Immunotherapeutics will enrol up to 400 patients for the first two stages of clinical trials of an experimental coronavirus vaccine.

---

⁍ Ose hopes to roll out its vaccine in Europe and the United States in 2022, potentially at least a year after the most advanced projects.

---

– France’s Ose Immunotherapeutics says it has an experimental vaccine in the works against the deadly strain of coronavirus that has killed more than a million people worldwide. The vaccine, which has yet to be tested on humans, targets a subgroup of T-cells, which are like “the infantry in our bodies,” CEO Alexis Peyroles tells Reuters. “T-cells are like the infantry in our bodies,” he says. “If you inject an antibodies vaccine several times to extend protection, you may end up seeing adverse reactions to the vaccine, that is where our product could also complement well.” The vaccine would be given to 400 patients in the first two stages of clinical trials by the end of the year, and the company hopes to have it available in the US and Europe by 2022, Peyroles says. Ose is one of a handful of companies working on coronavirus vaccines, and the only one working on a T-cell-based approach, according to the World Health Organization’s vaccination list.